Citations (68)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Anna Wolska-Washer, Piotr Smolewski & Tadeusz Robak. (2021) Advances in the pharmacotherapeutic options for primary nodal peripheral T-cell lymphoma. Expert Opinion on Pharmacotherapy 22:9, pages 1203-1215.
Read now
Read now
Wei Guan, Yu Jing, Liping Dou, Maoquan Wang, Yang Xiao & Li Yu. (2020) Chidamide in combination with chemotherapy in refractory and relapsed T lymphoblastic lymphoma/leukemia. Leukemia & Lymphoma 61:4, pages 855-861.
Read now
Read now
Nada Ahmed & Andrew L. Feldman. (2020) Targeting epigenetic regulators in the treatment of T-cell lymphoma. Expert Review of Hematology 13:2, pages 127-139.
Read now
Read now
Joshua S. Mervis & Jean S. McGee. (2019) Epigenetic therapy and dermatologic disease: moving beyond CTCL. Journal of Dermatological Treatment 30:1, pages 68-73.
Read now
Read now
Mauro Alaibac. (2018) Small molecule inhibitors for cutaneous T-cell lymphomas. Expert Opinion on Orphan Drugs 6:5, pages 345-350.
Read now
Read now
Andrei Shustov, Bertrand Coiffier, Steven Horwitz, Lubomir Sokol, Barbara Pro, Julie Wolfson, Barbara Balser, Robin Eisch, Leslie Popplewell, H. Miles Prince, Steven L. Allen, Richard Piekarz & Susan Bates. (2017) Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials. Leukemia & Lymphoma 58:10, pages 2335-2341.
Read now
Read now
Articles from other publishers (62)
Brianna M. Flores, Chandana K. Uppalapati, Agnes S. Pascual, Alan Vong, Margaux A. Baatz, Alisha M. Harrison, Kathryn J. Leyva & Elizabeth E. Hull. (2023) Biological Effects of HDAC Inhibitors Vary with Zinc Binding Group: Differential Effects on Zinc Bioavailability, ROS Production, and R175H p53 Mutant Protein Reactivation. Biomolecules 13:11, pages 1588.
Crossref
Crossref
Yang Yang, Biao Ma, Mahbod Djamshidi, Qingrun Zhang, Anusi Sarkar, Ayan Chanda, Uyen Tran, Jung Soh, Christina Sandall, Huey-Miin Chen, Justin A. MacDonald, Shirin Bonni, Christoph W. Sensen, Jianhua Zheng & Karl Riabowol. (2023) ING1 inhibits Twist1 expression to block EMT and is antagonized by the HDAC inhibitor vorinostat. European Journal of Cell Biology 102:3, pages 151341.
Crossref
Crossref
Yuan-hong Huang, Chao-Ling Wan, Hai-ping Dai & Sheng-li Xue. (2023) Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia/lymphoma. Annals of Hematology 102:8, pages 2001-2013.
Crossref
Crossref
Han‐Yu Cao, Ling Li, Sheng‐Li Xue & Hai‐Ping Dai. (2022) Chidamide: Targeting epigenetic regulation in the treatment of hematological malignancy. Hematological Oncology 41:3, pages 301-309.
Crossref
Crossref
Vibor Milunović, Inga Mandac Smoljanović, Martina Bogeljić Patekar, Viktor Zatezalo, Marin Kursar, Delfa Radić-Krišto, Slobodanka Ostojić Kolonić & Slavko Gašparov. (2023) First-Line Therapy for Nodal T-cell Non-Hodgkin Lymphomas: an Unmet Need in Hematology. Current Oncology Reports 25:7, pages 813-824.
Crossref
Crossref
Tao Liang, Fengli Wang, Reham M. Elhassan, Yongmei Cheng, Xiaolei Tang, Wengang Chen, Hao Fang & Xuben Hou. (2023) Targeting histone deacetylases for cancer therapy: Trends and challenges. Acta Pharmaceutica Sinica B 13:6, pages 2425-2463.
Crossref
Crossref
Jinghong Chen, Zhixiang Zuo, Yan Gao, Xiaosai Yao, Peiyong Guan, Yali Wang, Zhimei Li, Zhilong Liu, Jing Han Hong, Peng Deng, Jason Yongsheng Chan, Daryl Ming Zhe Cheah, Jingquan Lim, Kelila Xin Ye Chai, Burton Kuan Hui Chia, Jane Wan Lu Pang, Joanna Koh, Dachuan Huang, Haixia He, Yichen Sun, Lizhen Liu, Shini Liu, Yuhua Huang, Xiaoxiao Wang, Hua You, Sahil Ajit Saraf, Nicholas Francis Grigoropoulos, Xiaoqiu Li, Jinxin Bei, Tiebang Kang, Soon Thye Lim, Bin Tean Teh, Huiqiang Huang, Choon Kiat Ong & Jing Tan. (2023) Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK/T-cell lymphoma to chidamide. Clinical Epigenetics 15:1.
Crossref
Crossref
Frederick Gibson, Ailish Hanly, Robert Fisher, W Austin Wyant, Muzhou Wu, Marianne Collard & Rhoda M Alani. (2023) Epigenetics and cutaneous neoplasms: from mechanism to therapy. Epigenomics 15:3, pages 167-187.
Crossref
Crossref
Surya K. De. 2023. Medicines for Cancer. Medicines for Cancer
205
411
.
Eliza Mari Kwesi-Maliepaard, Muddassir Malik, Tibor van Welsem, Remco van Doorn, Maarten H. Vermeer, Hanneke Vlaming, Heinz Jacobs & Fred van Leeuwen. (2022) DOT1L inhibition does not modify the sensitivity of cutaneous T cell lymphoma to pan-HDAC inhibitors in vitro. Frontiers in Genetics 13.
Crossref
Crossref
Dehua Lu, Cheng Wang, Lailiang Qu, Fucheng Yin, Shang Li, Heng Luo, Yonglei Zhang, Xingchen Liu, Xinye Chen, Zhongwen Luo, Ningjie Cui, Lingyi Kong & Xiaobing Wang. (2022) Histone Deacetylase and Enhancer of Zeste Homologue 2 Dual Inhibitors Presenting a Synergistic Effect for the Treatment of Hematological Malignancies. Journal of Medicinal Chemistry 65:19, pages 12838-12859.
Crossref
Crossref
Claudio Brancolini, Teresa Gagliano & Martina Minisini. (2022) HDACs and the epigenetic plasticity of cancer cells: Target the complexity. Pharmacology & Therapeutics 238, pages 108190.
Crossref
Crossref
Suheil Albert Atallah-Yunes, Michael J. Robertson & Utpal P. Davé. (2022) Epigenetic Aberrations and Targets in Peripheral T-Cell Lymphoma. Clinical Lymphoma Myeloma and Leukemia 22:9, pages 659-665.
Crossref
Crossref
Zachary Braunstein, Miguel Ruiz, Walter Hanel, Polina Shindiapina, John C. Reneau & Jonathan E. Brammer. (2022) Recent Advances in the Management of Relapsed and Refractory Peripheral T-Cell Lymphomas. Journal of Personalized Medicine 12:6, pages 964.
Crossref
Crossref
Zhen-Dong He, Hai-Yan Yang, Sheng-Sheng Zhou, Man Wang, Qin-Li Mo, Feng-Xiang Huang & Zhi-Gang Peng. (2022) Chidamide combined with traditional chemotherapy for primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma: A case report. World Journal of Clinical Cases 10:4, pages 1341-1348.
Crossref
Crossref
Walter G. Hanel, Catherine G. Chung, Nikol Mladkova, Michael Weldon, Basem William & Meng Xu-Welliver. 2022. Radiation Therapy for Sarcomas and Skin Cancers. Radiation Therapy for Sarcomas and Skin Cancers
363
380
.
Ines Schmidts, Torsten Haferlach & Gregor Hoermann. 2022.
Andrey D. Bondarev, Misty M. Attwood, Jörgen Jonsson, Vladimir N. Chubarev, Vadim V. Tarasov & Helgi B. Schiöth. (2021) Recent developments of HDAC inhibitors: Emerging indications and novel molecules. British Journal of Clinical Pharmacology 87:12, pages 4577-4597.
Crossref
Crossref
Ying-Ying Ma, Quan-Chao Zhang, Xu Tan, Xi Zhang & Cheng Zhang. (2021) T-cell lymphoblastic lymphoma with extensive thrombi and cardiac thrombosis: A case report and review of literature. World Journal of Clinical Cases 9:31, pages 9607-9616.
Crossref
Crossref
Zainab Abdelghani, Nancy Hourani, Zahraa Zaidan, Ghassan Dbaibo, Marguerite Mrad & Rouba Hage-Sleiman. (2021) Therapeutic applications and biological activities of bacterial bioactive extracts. Archives of Microbiology 203:8, pages 4755-4776.
Crossref
Crossref
Afua Adjeiwaa Mensah, Filippo Spriano, Giulio Sartori, Valdemar Priebe, Luciano Cascione, Eugenio GaudioChiara Tarantelli, Elisa CivanelliLuca Aresu, Andrea Rinaldi, Giovanna Damia, Emanuela LovatiEmanuele Zucca, Anastasios Stathis, Claudio PietraFrancesco Bertoni. (2021) Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors. Blood Advances 5:10, pages 2467-2480.
Crossref
Crossref
Annika P. Schnell, Stephan Kohrt & Andrea K. Thoma-Kress. (2021) Latency Reversing Agents: Kick and Kill of HTLV-1?. International Journal of Molecular Sciences 22:11, pages 5545.
Crossref
Crossref
Moustafa S. Ghanem, Fiammetta Monacelli & Alessio Nencioni. (2021) Advances in NAD-Lowering Agents for Cancer Treatment. Nutrients 13:5, pages 1665.
Crossref
Crossref
Vicente FresquetMaria J. Garcia-Barchino, Marta Larrayoz, Jon Celay, Carmen Vicente, Marta Fernandez-GalileaMaria J. Larrayoz, Maria J. CalasanzCarlos PanizoAlexandra Junza, Jiahuai HanCelia PriorPuri Fortes, Ruben Pio, Julen Oyarzabal, Alvaro Martinez-BaztanBruno PaivaMaria J. Moreno-Aliaga, Maria D. Odero, Xabier AgirreOscar YanesFelipe Prosper & Jose A. Martinez-Climent. (2021) Endogenous Retroelement Activation by Epigenetic Therapy Reverses the Warburg Effect and Elicits Mitochondrial-Mediated Cancer Cell Death. Cancer Discovery 11:5, pages 1268-1285.
Crossref
Crossref
Seok Jin Kim, Ritsuro Suzuki, Arnaud Jaccard, Soon Thye Lim & Won Seog Kim. 2021. The Peripheral T‐Cell Lymphomas. The Peripheral T‐Cell Lymphomas
159
173
.
Yunlong HeNagesh PasupalaHuijun ZhiBatsuhk DorjbalImran HussainHsiu-Ming ShihSharmistha Bhattacharyya, Roopa BiswasMilos Miljkovic, Oliver John Semmes, Thomas A. Waldmann, Andrew L. Snow & Chou-Zen Giam. (2021) NF-κB–induced R-loop accumulation and DNA damage select for nucleotide excision repair deficiencies in adult T cell leukemia. Proceedings of the National Academy of Sciences 118:10.
Crossref
Crossref
Eftiola Pojani & Daniela Barlocco. (2021) Romidepsin (FK228), A Histone Deacetylase Inhibitor and its Analogues in Cancer Chemotherapy. Current Medicinal Chemistry 28:7, pages 1290-1303.
Crossref
Crossref
Shunhao Zhang, Yanji Gong, Chunjie Li, Wenbin Yang & Longjiang Li. (2020) Beyond regulations at DNA levels: A review of epigenetic therapeutics targeting cancer stem cells. Cell Proliferation 54:2.
Crossref
Crossref
Pengfei Wang, Qijie Gong, Jiabao Hu, Xiang Li & Xiaojin Zhang. (2020) Reactive Oxygen Species (ROS)-Responsive Prodrugs, Probes, and Theranostic Prodrugs: Applications in the ROS-Related Diseases. Journal of Medicinal Chemistry 64:1, pages 298-325.
Crossref
Crossref
Donal J. Cox, Amy M. Coleman, Karl M. Gogan, James J. Phelan, Cilian Ó Maoldomhnaigh, Pádraic J. Dunne, Sharee A. Basdeo & Joseph Keane. (2020) Inhibiting Histone Deacetylases in Human Macrophages Promotes Glycolysis, IL-1β, and T Helper Cell Responses to Mycobacterium tuberculosis. Frontiers in Immunology 11.
Crossref
Crossref
Daniella Klebaner, Divya Koura, Dimitrios Tzachanis, Edward D. Ball, Steven Horwitz & Aaron M. Goodman. (2020) Intensive Induction Therapy Compared With CHOP for Hepatosplenic T-cell Lymphoma. Clinical Lymphoma Myeloma and Leukemia 20:7, pages 431-437.e2.
Crossref
Crossref
Malgorzata Bobrowicz, Aleksander Slusarczyk, Joanna Domagala, Michal Dwojak, Desislava Ignatova, Yun‑Tsan Chang, Christoph Iselin, Nina Miazek‑Zapala, Katsiaryna Marhelava, Emmanuella Guenova & Magdalena Winiarska. (2020) Selective inhibition of HDAC6 sensitizes cutaneous T‑cell lymphoma to PI3K inhibitors. Oncology Letters 20:1, pages 533-540.
Crossref
Crossref
Matthew A. Timmins, Simon D. Wagner & Matthew J. Ahearne. (2020) The new biology of PTCL‐NOS and AITL: current status and future clinical impact. British Journal of Haematology 189:1, pages 54-66.
Crossref
Crossref
Chiara TarantelliMartin LangeEugenio GaudioLuciano Cascione, Filippo SprianoIvo KweeAlberto J. ArribasAndrea Rinaldi, Thibaud JourdanMelanie BertholdAndrea SturzCarolyn SperlFrancesco MargheritiLorenzo ScaliseGiuseppe GrittiDavide Rossi, Anastasios Stathis, Ningshu LiuEmanuele Zucca, Oliver Politz & Francesco Bertoni. (2020) Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models. Blood Advances 4:5, pages 819-829.
Crossref
Crossref
Ying Wu, Lei Wang, Yahui Huang, Shuqiang Chen, Shanchao Wu, Guoqiang Dong & Chunquan Sheng. (2019) Nicotinamide Phosphoribosyltransferase (NAMPT) Is a New Target of Antitumor Agent Chidamide. ACS Medicinal Chemistry Letters 11:1, pages 40-44.
Crossref
Crossref
Patricia Hamminger, Ramona Rica & Wilfried Ellmeier. 2020.
1
59
.
Shan Pan, Jun Leng, Xinzhou Deng, Honggang Ruan, Lu Zhou, Muhammad Jamal, Ruijing Xiao, Jie Xiong, Qian Yin, Yingjie Wu, Meng Wang, Wen Yuan, Liang Shao & Qiuping Zhang. (2019) Nicotinamide increases the sensitivity of chronic myeloid leukemia cells to doxorubicin via the inhibition of SIRT1. Journal of Cellular Biochemistry 121:1, pages 574-586.
Crossref
Crossref
Linyu Yang, Qiang Qiu, Minghai Tang, Fang Wang, Yuyao Yi, Dongni Yi, Zhuang Yang, Zejiang Zhu, Shoujun Zheng, Jianhong Yang, Heying Pei, Li Zheng, Yong Chen, Liping Gou, Liya Luo, Xing Deng, Haoyu Ye, Yiguo Hu, Ting Niu & Lijuan Chen. (2019)
Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of
BCR-ABL
–Induced B-Cell Acute Lymphoblastic Leukemia
. Clinical Cancer Research 25:24, pages 7527-7539.
Crossref
Crossref
Megan H. Trager & Larisa J. Geskin. (2019) Current status of histone deacetylase inhibitors in cutaneous T-cell lymphoma. Giornale Italiano di Dermatologia e Venereologia 154:6.
Crossref
Crossref
Iman Mamdouh Talaat, Rania ElSaied Abdelmaksoud, Maha Guimei, Naglaa Fathi Agamia, Ahmed Nugud & Ahmed Taher El-Serafi. (2019) Potential role for microRNA-16 (miR-16) and microRNA-93 (miR-93) in diagnosis and prediction of disease progression in mycosis fungoides in Egyptian patients. PLOS ONE 14:10, pages e0224305.
Crossref
Crossref
Chen, Lin, Liao, Liou & Chen. (2019) MPT0G612, a Novel HDAC6 Inhibitor, Induces Apoptosis and Suppresses IFN-γ-Induced Programmed Death-Ligand 1 in Human Colorectal Carcinoma Cells. Cancers 11:10, pages 1617.
Crossref
Crossref
Keri Toner, Catherine M. Bollard & Hema Dave. (2019) T-cell therapies for T-cell lymphoma. Cytotherapy 21:9, pages 935-942.
Crossref
Crossref
Sheng Wang, Dexi Zhou, Zhenyu Xu, Jing Song, Xueyi Qian, Xiongwen Lv & Jiajie Luan. (2019) Anti-tumor Drug Targets Analysis: Current Insight and Future Prospect. Current Drug Targets 20:11, pages 1180-1202.
Crossref
Crossref
Chunchen Yuan, Ping Dai, Xiaoguang Bao & Yingsheng Zhao. (2019) Highly Site-Selective Formation of Perfluoroalkylated Anilids via a Protecting Strategy by Molybdenum Hexacarbonyl Catalyst. Organic Letters 21:16, pages 6481-6484.
Crossref
Crossref
Matthew J. Barth & Veronique Minard‐Colin. (2019) Novel targeted therapeutic agents for the treatment of childhood, adolescent and young adult non‐Hodgkin lymphoma. British Journal of Haematology 185:6, pages 1111-1124.
Crossref
Crossref
Dusan Ruzic, Milos Petkovic, Danica Agbaba, A. Ganesan & Katarina Nikolic. (2019) Combined Ligand and Fragment‐based Drug Design of Selective Histone Deacetylase – 6 Inhibitors. Molecular Informatics 38:5, pages 1800083.
Crossref
Crossref
Reece G. Kenny & Celine J. Marmion. 2019. Metal-based Anticancer Agents. Metal-based Anticancer Agents
1
30
.
Yannick Tauran, Momoko Kumemura, Mehmet C. Tarhan, Grégoire Perret, Florent Perret, Laurent Jalabert, Dominique Collard, Hiroyuki Fujita & Anthony W. Coleman. (2019) Direct measurement of the mechanical properties of a chromatin analog and the epigenetic effects of para-sulphonato-calix[4]arene. Scientific Reports 9:1.
Crossref
Crossref
Coraline Mlynarczyk, Lorena Fontán & Ari Melnick. (2019) Germinal center‐derived lymphomas: The darkest side of humoral immunity. Immunological Reviews 288:1, pages 214-239.
Crossref
Crossref
Rashmi R. Shah. (2019) Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology. Drug Safety 42:2, pages 235-245.
Crossref
Crossref
Reece G. Kenny & Celine J. Marmion. (2019) Toward Multi-Targeted Platinum and Ruthenium Drugs—A New Paradigm in Cancer Drug Treatment Regimens?. Chemical Reviews 119:2, pages 1058-1137.
Crossref
Crossref
Hongyu Zhang, Jianping Lu, Yun Jiao, Qi Chen, Min Li, Zichen Wang, Zhendong Yu, Xiaodong Huang, Athena Yao, Qiong Gao, Weiguo Xie, Ling Li & Paul Yao. (2019) Aspirin Inhibits Natural Killer/T-Cell Lymphoma by Modulation of VEGF Expression and Mitochondrial Function. Frontiers in Oncology 8.
Crossref
Crossref
Avirup Guha, Merna Armanious & Michael G. Fradley. (2019) Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities. Trends in Cardiovascular Medicine 29:1, pages 29-39.
Crossref
Crossref
Jing Jing Han, Megan O’byrne, Mary J. Stenson, Matthew J. Maurer, Linda E. Wellik, Andrew L. Feldman, Ellen D. McPhail, Thomas E. Witzig & Mamta Gupta. (2018) Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphoma. Blood Cancer Journal 8:11.
Crossref
Crossref
Somnath D. Bhagat, Usha Singh, Ram Kumar Mishra & Aasheesh Srivastava. (2018) An Endogenous Reactive Oxygen Species (ROS)‐Activated Histone Deacetylase Inhibitor Prodrug for Cancer Chemotherapy. ChemMedChem 13:19, pages 2073-2079.
Crossref
Crossref
Wilfried Ellmeier & Christian Seiser. (2018) Histone deacetylase function in CD4+ T cells. Nature Reviews Immunology 18:10, pages 617-634.
Crossref
Crossref
Genevieve Tyndale Clutton & R. Brad Jones. (2018) Diverse Impacts of HIV Latency-Reversing Agents on CD8+ T-Cell Function: Implications for HIV Cure. Frontiers in Immunology 9.
Crossref
Crossref
Aditya Kulkarni, Paola Caporali, Atul Dolas, Soniya Johny, Sandeep Goyal, Jessica Dragotto, Alberto Macone, Ramesh Jayaraman & Maria Teresa Fiorenza. (2018) Linear Cyclodextrin Polymer Prodrugs as Novel Therapeutics for Niemann-Pick Type C1 Disorder. Scientific Reports 8:1.
Crossref
Crossref
Lisa Göschl, Teresa Preglej, Patricia Hamminger, Michael Bonelli, Liisa Andersen, Nicole Boucheron, Alexandra F. Gülich, Lena Müller, Victoria Saferding, Ilgiz A. Mufazalov, Kiyoshi Hirahara, Christian Seiser, Patrick Matthias, Thomas Penz, Michael Schuster, Christoph Bock, Ari Waisman, Günter Steiner & Wilfried Ellmeier. (2018) A T cell-specific deletion of HDAC1 protects against experimental autoimmune encephalomyelitis. Journal of Autoimmunity 86, pages 51-61.
Crossref
Crossref
Kelly A. Hyndman & Mark A. Knepper. (2017) Dynamic regulation of lysine acetylation: the balance between acetyltransferase and deacetylase activities. American Journal of Physiology-Renal Physiology 313:4, pages F842-F846.
Crossref
Crossref
Staci L. Haney, Cheryl Allen, Michelle L. Varney, Kaitlyn M. Dykstra, Eric R. Falcone, Sean H. Colligan, Qiang Hu, Alyssa M. Aldridge, Dennis L. Wright, Andrew J. Wiemer & Sarah A. Holstein. (2017) Novel tropolones induce the unfolded protein response pathway and apoptosis in multiple myeloma cells. Oncotarget 8:44, pages 76085-76098.
Crossref
Crossref
Marcelo Gomes, Eugene Muratov, Maristela Pereira, Josana Peixoto, Lucimar Rosseto, Pedro Cravo, Carolina Andrade & Bruno Neves. (2017) Chalcone Derivatives: Promising Starting Points for Drug Design. Molecules 22:8, pages 1210.
Crossref
Crossref